Koyfin Home > Directory > Health Care > Amicus Therapeutics > EBITDA

Amicus Therapeutics EBITDA Chart (FOLD)

Amicus Therapeutics annual/quarterly EBITDA from 2006 to 2018. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Amicus Therapeutics EBITDA for the quarter ending December 12, 2018 was $-68m a 20.09% decrease of -14m year over year
  • Amicus Therapeutics EBITDA for the last 12 months ending December 12, 2018 was $-321m a 35.81% decrease of -115m year over year
  • Amicus Therapeutics Annual EBITDA for 2018 was $-321m a 35.43% decrease of -114m from 2017
  • Amicus Therapeutics Annual EBITDA for 2017 was $-208m a 17.22% decrease of -36m from 2016
  • Amicus Therapeutics Annual EBITDA for 2016 was $-172m a 27.71% decrease of -48m from 2015
Other Income Statement Metrics:
  • Amicus Therapeutics Net Income for the quarter ending December 12, 2018 was $-78m a 36.07% decrease of -28m year over year
  • Amicus Therapeutics Total Revenue for the quarter ending September 09, 2018 was $21m a 28.49% increase of 6m year over year
View Chart On Koyfin

Quarterly FOLD EBITDA Data

12/2018$-68m
09/2018$-154m
06/2018$-46m
03/2018$-54m
12/2017$-54m
09/2017$-53m
06/2017$-45m
03/2017$-47m
12/2016$-53m
09/2016$-42m

Annual FOLD EBITDA Data

2018$-321m
2017$-208m
2016$-172m
2015$-124m
2014$-67m
2013$-60m
2012$-51m
2011$-49m
2010$-54m
2009$-4m